100 related articles for article (PubMed ID: 18596360)
21. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Bachawal SV; Wali VB; Sylvester PW
BMC Cancer; 2010 Mar; 10():84. PubMed ID: 20211018
[TBL] [Abstract][Full Text] [Related]
23. A new therapeutic antibody masks ErbB2 to its partners.
Badache A; Hynes NE
Cancer Cell; 2004 Apr; 5(4):299-301. PubMed ID: 15093533
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.
Pickl M; Ries CH
Oncogene; 2009 Jan; 28(3):461-8. PubMed ID: 18978815
[TBL] [Abstract][Full Text] [Related]
25. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
26. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
27. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
Mocanu MM; Fazekas Z; Petrás M; Nagy P; Sebestyén Z; Isola J; Tímár J; Park JW; Vereb G; Szöllosi J
Cancer Lett; 2005 Sep; 227(2):201-12. PubMed ID: 16112423
[TBL] [Abstract][Full Text] [Related]
28. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
30. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
33. EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements.
Nagy P; Bene L; Balázs M; Hyun WC; Lockett SJ; Chiang NY; Waldman F; Feuerstein BG; Damjanovich S; Szöllosi J
Cytometry; 1998 Jun; 32(2):120-31. PubMed ID: 9627225
[TBL] [Abstract][Full Text] [Related]
34. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
36. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
[TBL] [Abstract][Full Text] [Related]
37. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
Hynes NE; Dey JH
Cancer Cell; 2009 May; 15(5):353-5. PubMed ID: 19411062
[TBL] [Abstract][Full Text] [Related]
38. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
39. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
Gong SJ; Jin CJ; Rha SY; Chung HC
Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
[TBL] [Abstract][Full Text] [Related]
40. A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines.
Kim EM; Lobocki C; Dubay L; Mittal VK
Am J Surg; 2009 Mar; 197(3):331-6. PubMed ID: 19245910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
